SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : Sharck Soup
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Sharck who started this subject5/10/2001 2:33:37 PM
From: besttrader  Read Replies (1) of 37746
 
14:31 ET Millennium Pharm (MLNM) 35.66 -1.58 (-4.2%): FDA grants accelerated approval of Campath as a treatment for patients with B-cell chronic lymphocytic leukemia (CLL), the most prevalent form of adult leukemia. Campath has been licensed by BTG (global technology commercialization company in London) to MLNM. With approval, Campath will become the first monoclonal antibody to be approved for the treatment of CLL and first new drug for treatment of CLL in nearly ten years.




14:09 ET Netegrity (NETE) 33.27 -2.63 (-7.3%): -- Technical -- Back testing bottom of recent range, April 25 low and 50 day simple ma (33.15/32.49). Posture above keeps bias neutral, failure at this barrier leaves the door open to the 29.50 area. Short term resistance is at 34.70/35.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News